

CURRICULUM VITAE  
**D. Eric Bolster, MD**

**BUSINESS ADDRESS**

Palmetto Clinical Research

***Investigator***

**1993-Present**

201 Oakbrook Lane, Summerville, SC 29485

Phone: 843.851.7098 Fax: 843.851.0394

Palmetto Primary Care Physicians

***Private Practice***

**1993-Present**

201 Oakbrook Lane, Summerville, SC 29485

**HOSPITAL AFFILIATIONS**

Trident Regional Medical Center

Charleston, SC

Summerville Medical Center

Summerville, SC 29485

**LICENSURE**

South Carolina

***Medical License Number: MMD.16913***

**1993-Present**

Virginia

**1989-1992**

**CERTIFICATION**

Board Certification

***Internal Medicine***

**1991-Present**

Association of Clinical Research Professionals

***Certified Principal Investigator***

**2015-2017**

Good Clinical Practice Training

**2016**

**EDUCATION**

Duke University School of Medicine, Durham, NC

***Medical Doctor***

**1984-1988**

The University of North Carolina, Chapel Hill, NC

***Bachelor of Arts, Chemistry***

**1980-1984**

**PROFESSIONAL TRAINING**

Naval Hospital, Portsmouth, VA

***Resident, Internal Medicine***

**1989-1991**

Naval Hospital, Portsmouth, VA

***Internship, Internal Medicine***

**1988-1989**

**POSITIONS/TITLES**

Medical University of South Carolina College of Medicine, Charleston, SC

***Clinical Assistant Professor of Medicine***

**1992-1994**


Naval Hospital, Charleston, SC

***Staff Internist***

**1989-1991**

Internal Medicine Department & Family Residency Program

**RESEARCH EXPERIENCE**



06 June 2016

**SEE ATTACHMENT****HONORS & AWARDS**

|                                                 |             |
|-------------------------------------------------|-------------|
| Phi Eta Sigma Freshman Honor Society            | 1981        |
| Alpha Epsilon Delta, Premedical Honor Society   | 1982 – 1984 |
| Phi Beta Kappa Honor Society                    | 1983        |
| Health Professions Scholarship Program, US Navy | 1984        |
| Alpha Omega Alpha Honor Society                 | 1987        |
| Hewlett Packard Medical Graduate Award          | 1988        |
| Aequanimitas Award                              | 1991        |
| Most Outstanding Senior Resident                | 1991        |
| Best Clinical Instructor in Internal Medicine   | 1992        |
| Best Clinical Instructor in Internal Medicine   | 1993        |

**PUBLICATIONS**

|                                                                                                                                                                                                                                                                       |      |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| R. Yee, K. Brown, D. Bolster, and H. Strauss<br><i>Relationship between ionic perturbations and electrophysiologic changes in canine Purkinje fiber model of ischemia and reperfusion.</i><br>J Clin Invest, 82:22-233                                                | 1988 |
| D. Eric Bolster, William E. Hatfield, and Leo Walter Haar<br><i>Exchange coupling in di-u-hydroxo-bis (S) alaninato Chromium (III), trihydrate.</i><br>Transition Metal Chemistry, 10:161-164                                                                         | 1985 |
| Michael, Megnamisi-Belcombe, D. Eric Bolster, Phirtu Singh, and William E. Hatfield<br><i>Catena-dichloro-(dipheny ethanedione) copper (II), a new one dimensional s=2 Heisenberg chain with a novel zig-zag structure.</i><br>Inorganic Chemistry, 23(17): 2578-2582 | 1984 |
| D. Eric Bolster, Phillip Gutlich, William E. Hatfield<br><i>Exchange coupling in tris (u-hydroxo)bis [(1,2,7-trimethyl-1, 4, 7-triazacyclononane) chromium(III)] triperchlorate trihydrate.</i><br>Inorganic Chemistry, 22(12): 1725-1729                             | 1983 |

**POSTER PRESENTATIONS**

|                                                                                                                                                               |      |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| <i>The effect of one hour noise exposure on cochlear blood flow.</i><br>Presented at the Association for Research in Otolaryngology Meeting, February 7, 1984 | 1984 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

**MEMBERSHIPS**

Association of Clinical Research Professionals

## Clinical Trial Experience: D. Eric Bolster, MD

| 1)  | Sponsor                   | Indication                                                 | From     | To       | Role  |
|-----|---------------------------|------------------------------------------------------------|----------|----------|-------|
| 2)  | Glaxo-Wellcome            | Migraine                                                   | Sep 1994 | Mar 1996 | Sub-I |
| 3)  | Pharmaco LSR              | Inpatient Community acquired pneumonia                     | Jan 1995 | Dec 1996 | Sub-I |
| 4)  | Parke Davis/Kendle        | Congestive Heart Failure                                   | Jan 1995 | Dec 1995 | Sub-I |
| 5)  | Baker Norton              | Acute Ischemic Stroke                                      | Apr 1996 | Nov 1997 | Sub-I |
| 6)  | Bristol Myers Squibb      | Mild to Moderate HTN                                       | Oct 1996 | Apr 1997 | Sub-I |
| 7)  | Searle/Parexel            | HTN with Cardiovascular endpoints                          | Oct 1996 | Dec 1998 | Sub-I |
| 8)  | Bayer                     | Acute Exacerbations of Chronic Bronchitis                  | Oct 1996 | May 1998 | Sub-I |
| 9)  | Bayer                     | Community Acquired Pneumonia                               | Nov 1996 | May 1998 | Sub-I |
| 10) | Janssen/ClinTrials        | Acute Migraine                                             | Jan 1997 | Apr 1997 | Sub-I |
| 11) | Janssen/ClinTrials        | Migraine                                                   | Mar 1997 | Jun 1997 | Sub-I |
| 12) | Pfizer/PPD Pharmaco       | Acute Sinusitis                                            | Mar 1997 | Sep 1997 | PI    |
| 13) | SCIOS                     | Decompensated CHF                                          | Apr 1997 | Jul 1997 | PI    |
| 14) | Bristol Myers Squibb      | Mild to Moderate HTN                                       | Jul 1997 | Oct 1997 | Sub-I |
| 15) | HMR/Quintiles             | Patients at risk of myocardial necrosis due to ACS         | Aug 1997 | Jul 1998 | Sub-i |
| 16) | Bristol Myers Squibb      | Hypertension                                               | Sep 1997 | Dec 1997 | Sub-I |
| 17) | Parke-Davis & Pfizer      | Hypercholesterolemia                                       | Oct 1997 | Jan 1998 | Sub-I |
| 18) | Glaxo Wellcome/ClinTrials | Irritable Bowel Syndrome                                   | Jan 1998 | Aug 1998 | PI    |
| 19) | Zeneca                    | Acute Migraine                                             | Mar 1998 | Jun 1998 | PI    |
| 20) | Ortho-McNeil              | Inpatient Serious Community Acquired Pneumonia             | May 1998 | Jan 2000 | Sub-I |
| 21) | Glaxo                     | Acute Bacterial Exacerbation of Chronic Bronchitis         | Jun 1998 | Mar 1999 | Sub-I |
| 22) | Glaxo                     | Community Acquired Pneumonia                               | Jun 1998 | Mar 1999 | PI    |
| 23) | SCIOS                     | Symptomatic, Decompensated CHF                             | Aug 1998 | Dec 1998 | PI    |
| 24) | Bristol Myers Squibb      | Mild to Moderate HTN                                       | Aug 1998 | Mar 1999 | PI    |
| 25) | Boehringer Ingelheim      | Benign Prostatic Hypertrophy                               | Sep 1998 | May 1999 | Sub-I |
| 26) | PPD/Pharmaco              | Acute Maxillary Sinusitis                                  | Oct 1998 | Dec 1998 | PI    |
| 27) | SmithKline Beecham        | Systolic Hypertension                                      | Nov 1998 | Mar 1999 | Sub-I |
| 28) | SmithKline Beecham        | Community Acquired Pneumonia                               | Nov 1998 | Jun 1999 | Sub-I |
| 29) | SmithKline Beecham        | Acute Exacerbation of Chronic Bronchitis                   | Nov 1998 | Apr 1999 | PI    |
| 30) | SmithKline Beecham        | Pyelonephritis or Complicated UTI                          | Nov 1998 | May 1999 | Sub-I |
| 31) | Glaxo                     | Irritable Bowel Syndrome                                   | Dec 1998 | May 1999 | PI    |
| 32) | Pfizer                    | Community Acquired Pneumonia or Acute Exacerbation of COPD | Dec 1998 | Mar 2000 | Sub-I |
| 33) | Novartis                  | Essential Hypertension                                     | Mar 1999 | Nov 1999 | Sub-I |
| 34) | Merck                     | Hypercholesterolemia                                       | Mar 1999 | Aug 1999 | Sub-I |

### Clinical Trial Experience: D. Eric Bolster, MD

|     |                      |                                                       |          |          |       |
|-----|----------------------|-------------------------------------------------------|----------|----------|-------|
| 35) | Glaxo                | Influenza                                             | Mar 1999 | Apr 1999 | Sub-I |
| 36) | SmithKline Beecham   | Type II Diabetes Mellitus                             | Aug 1999 | Feb 2000 | Sub-I |
| 37) | Novo Nordisk         | Insulin Dependent Type II Diabetes Mellitus           | Sep 1999 | Feb 1999 | Sub-I |
| 38) | Novo Nordisk         | Type II Diabetes                                      | Sep 1999 | Mar 2000 | Sub-I |
| 39) | Bristol Myers Squibb | Acute Maxillary Sinusitis                             | Sep 1999 | Dec 1999 | PI    |
| 40) | Abbott               | Community Acquired Pneumonia                          | Nov 1999 | May 2000 | PI    |
| 41) | SmithKline Beecham   | Acute Exacerbation of Chronic Bronchitis              | Nov 1999 | Feb 2000 | PI    |
| 42) | SmithKline Beecham   | Bacterial Community Acquired Pneumonia                | Dec 1999 | Jun 2002 | Sub-I |
| 43) | Bristol Myers Squibb | Acute Stroke                                          | Dec 1999 | Nov 2000 | PI    |
| 44) | Glaxo Wellcome       | Irritable Bowel Syndrome                              | Dec 1999 | Jul 2000 | PI    |
| 45) | Glaxo Wellcome       | Irritable Bowel Syndrome                              | Dec 1999 | Jun 2000 | PI    |
| 46) | Bayer                | Inpatient Community Acquired Pneumonia                | Dec 1999 | May 2000 | Sub-I |
| 47) | SmithKline Beecham   | Influenza                                             | Jan 2000 | Mar 2000 | Sub-I |
| 48) | Novo Nordisk         | Type II Diabetes Mellitus                             | Feb 2000 | Dec 2000 | Sub-I |
| 49) | Merck                | Osteoarthritis                                        | Apr 2000 | Aug 2000 | Sub-I |
| 50) | SmithKline Beecham   | Hyperlipidemia                                        | May 2000 | Aug 2000 | Sub-I |
| 51) | Bristol Myers Squibb | C-Reactive Protein                                    | Jun 2000 | Jun 2000 | Sub-I |
| 52) | Glaxo Wellcome       | Asthma                                                | Jun 2000 | Aug 2000 | Sub-I |
| 53) | Glaxo Wellcome       | Irritable Bowel Syndrome                              | Jul 2000 | Oct 2000 | PI    |
| 54) | SmithKline Beecham   | Acute Exacerbations of Chronic Bronchitis             | Oct 2000 | Jan 2001 | PI    |
| 55) | Bristol Myers Squibb | Hypertension                                          | Oct 2000 | Jan 2001 | Sub-I |
| 56) | Bayer                | Community Acquired Pneumonia                          | Nov 2000 | Jun 2002 | Sub-I |
| 57) | Abbott Laboratories  | Community Acquired Pneumonia                          | Dec 2000 | Dec 2001 | PI    |
| 58) | Glaxo SmithKline     | Inpatient Community Acquired Pneumonia                | Dec 2000 | Jan 2000 | Sub-I |
| 59) | Pfizer               | Acute Bacterial Sinusitis                             | Mar 2001 | Dec 2001 | Sub-I |
| 60) | Glaxo SmithKline     | Pneumonia                                             | Apr 2001 | Feb 2002 | Sub-I |
| 61) | Astra Zeneca         | Hypercholesterolemia                                  | May 2001 | Dec 2001 | PI    |
| 62) | Astra Zeneca         | Hypercholesterolemia                                  | May 2001 | May 2002 | PI    |
| 63) | Bayer                | Pneumonia                                             | Jun 2001 | Feb 2002 | Sub-I |
| 64) | Bayer                | Complicated UTI or Acute Uncomplicated Pyelonephritis | Jul 2001 | Jun 2002 | Sub-I |
| 65) | Bayer                | Acute Exacerbation of Chronic Bronchitis              | Jul 2001 | Apr 2002 | Sub-I |
| 66) | Glaxo SmithKline     | Type II Diabetics with HTN                            | Jul 2001 | Jul 2003 | Sub-I |
| 67) | Bayer                | Urinary Tract Infection                               | Sep 2001 | Jan 2002 | Sub-I |
| 68) | Bristol Myers Squibb | Type II Diabetes                                      | Nov 2001 | Jun 2006 | PI    |
| 69) | Glaxo SmithKline     | Acute Exacerbations of Chronic Bronchitis             | Dec 2001 | Apr 2002 | Sub-I |
| 70) | Astra Zeneca         | Hypercholesterolemia                                  | Feb 2002 | May 2003 | PI    |
| 71) | Pfizer               | Acute Exacerbations of Chronic Bronchitis             | Mar 2002 | Dec 2002 | Sub-I |
| 72) | Novartis             | Osteoarthritis                                        | Apr 2002 | Dec 2002 | Sub-I |

## Clinical Trial Experience: D. Eric Bolster, MD


|      |                       |                                             |          |           |       |
|------|-----------------------|---------------------------------------------|----------|-----------|-------|
| 73)  | Merck                 | Combined Hyperlipidemia                     | Jun 2002 | Feb 2003  | Sub-I |
| 74)  | Glaxo SmithKline      | Irritable Bowe Syndrome                     | Jul 2002 | Oct 2002  | PI    |
| 75)  | Astra Zeneca          | Type II Diabetes                            | Oct 2002 | Jan 2003  | Sub-I |
| 76)  | Abbott                | Pneumonia                                   | Oct 2002 | Nov 2002  | PI    |
| 77)  | Glaxo SmithKline      | Type II Diabetes                            | Mar 2003 | Oct 2003  | PI    |
| 78)  | Bristol Myers Squibb  | Type II Diabetes                            | Jun 2003 | Oct 2003  | PI    |
| 79)  | Bristol Myers Squibb  | Type II Diabetes                            | Jun 2003 | Oct 2003  | PI    |
| 80)  | Astra Zeneca          | Hypercholesterolemia                        | Aug 2003 | Jan 2004  | PI    |
| 81)  | Bayer                 | Urinary Tract Infections                    | Aug 2003 | Oct 2003  | Sub-I |
| 82)  | Novartis              | Hypertension                                | Sep 2003 | Mar 2004  | Sub-I |
| 83)  | Pfizer                | Pneumonia                                   | Oct 2003 | Feb 2004  | Sub-I |
| 84)  | Glaxo SmithKline      | Irritable Bowel Syndrome                    | Oct 2003 | Sep 2005  | PI    |
| 85)  | Bayer                 | Pneumonia                                   | Oct 2003 | Mar 2004  | Sub-I |
| 86)  | Bristol Myers Squibb  | Severe Hypertension                         | Oct 2003 | Mar 2004  | PI    |
| 87)  | Bristol Myers Squibb  | Moderate Hypertension                       | Oct 2003 | Dec 2004  | PI    |
| 88)  | Merck                 | Osteoporosis                                | Dec 2003 | Mar 2004  | Sub-I |
| 89)  | Wyeth Research        | Inpatient Pneumonia                         | Jan 2004 | Jun 2005  | Sub-I |
| 90)  | Peninsula Pharma      | Lower UTI or Pyelonephritis                 | Aug 2004 | Feb 2006  | Sub-I |
| 91)  | Pfizer                | Osteoarthritis                              | Sep 2004 | Jan 2005  | Sub-I |
| 92)  | Pozen                 | Migraine                                    | Sep 2004 | Dec 2004  | Sub-I |
| 93)  | Novartis              | Essential Hypertension                      | Mar 2005 | July 2005 | Sub-I |
| 94)  | Pfizer                | Fibromyalgia                                | Nov 2005 | Apr 2006  | Sub-I |
| 95)  | Pfizer                | Fibromyalgia                                | Nov 2005 | Jul 2006  | Sub-I |
| 96)  | Glaxo SmithKline      | Acute Exacerbation of COPD                  | Dec 2005 | Jul 2006  | PI    |
| 97)  | Ortho McNeal          | Complicated UTI/Acute Pyelonephritis        | Dec 2005 | Mar 2006  | Sub-I |
| 98)  | Novartis              | Hypertension                                | Dec 2006 | Jul 2006  | PI    |
| 99)  | Novartis              | Hypertension                                | Jan 2006 | Jun 2006  | Sub-I |
| 100) | Aventis               | Respiratory Tract Infections                | Jan 2006 | Sep 2006  | Sub-I |
| 101) | Pfizer                | Osteoarthritis                              | Feb 2006 | Jul 2006  | Sub-I |
| 102) | Abbott                | Mixed Dyslipidemia                          | Apr 2006 | Jul 2006  | Sub-I |
| 103) | Boehringer Ingelheim  | Atrial Fibrillation                         | Apr 2006 | Dec 2007  | PI    |
| 104) | Advanced Life Science | Pneumonia                                   | May 2006 | Sep 2007  | PI    |
| 105) | Wyeth                 | Fibromyalgia                                | Jul 2006 | Jun 2007  | Sub-I |
| 106) | Speedel               | Diabetic Nephropathy                        | Sep 2006 | Dec 2006  | Sub-I |
| 107) | Abbott                | Mixed Dyslipidemia                          | Sep 2006 | Dec 2007  | Sub-I |
| 108) | Wyeth                 | Fibromyalgia                                | Jan 2007 | Dec 2007  | Sub-I |
| 109) | Pfizer                | Osteoarthritis/<br>Rheumatoid Arthritis     | Jan 2007 | ONGOING   | Sub-I |
| 110) | Microbia              | Chronic Constipation                        | Jan 2007 | Nov 2007  | PI    |
| 111) | Novartis              | Type II Diabetes                            | Jan 2007 | Aug 2007  | PI    |
| 112) | Pfizer                | Osteoarthritis                              | Mar 2007 | Jun 2007  | Sub-I |
| 113) | Microbia              | Irritable Bowel Syndrome                    | Apr 2007 | Aug 2007  | PI    |
| 114) | Merck                 | Hypercholesterolemia/<br>Mixed Dyslipidemia | Aug 2007 | Mar 2008  | Sub-I |
| 115) | Boehringer Ingelheim  | Venous thromboembolism                      | Aug 2007 | Jan 2010  | PI    |
| 116) | Boehringer Ingelheim  | Acute symptomatic venous thromboembolism    | Aug 2007 | Jan 2010  | PI    |

### Clinical Trial Experience: D. Eric Bolster, MD

|      |                         |                                                |          |          |       |
|------|-------------------------|------------------------------------------------|----------|----------|-------|
| 117) | Bristol Myers Squibb    | Type II Diabetes                               | Sep 2007 | Apr 2008 | PI    |
| 118) | Merck                   | Type II Diabetes                               | Oct 2007 | Jun 2008 | Sub-I |
| 119) | Boehringer<br>Ingelheim | Venous Thromboembolism                         | Feb 2008 | Dec 2008 | PI    |
| 120) | Boehringer<br>Ingelheim | Venous Thromboembolism                         | Feb 2008 | Dec 2008 | PI    |
| 121) | Merck                   | Hypertension                                   | Apr 2008 | Jun 2008 | PI    |
| 122) | Abbott                  | Atherogenic Dyslipidemia                       | Apr 2008 | Jun 2008 | Sub-I |
| 123) | Pfizer                  | Overactive Bladder                             | Apr 2008 | Jun 2009 | Sub-I |
| 124) | Cogentus                | Gastrointestinal Events                        | Apr 2008 | Nov 2008 | Sub-I |
| 125) | Bristol Myers Squibb    | Type II Diabetes/ Moderate<br>Renal Impairment | Aug 2008 | Dec 2009 | PI    |
| 126) | Boehringer<br>Ingelheim | Acute symptomatic venous<br>thromboembolism    | Aug 2008 | Jan 2010 | PI    |
| 127) | Bristol Myers Squibb    | Type 2 Diabetes and Renal<br>Impairment        | Aug 2008 | Aug 2010 | PI    |
| 128) | Bristol Myers Squibb    | Type II Diabetes                               | Aug 2008 | Dec 2008 | PI    |
| 129) | Merck                   | Hypercholesterolemia/<br>Mixed Hyperlipidemia  | Aug 2008 | Mar 2009 | Sub-I |
| 130) | Boehringer<br>Ingelheim | Venous Thromboembolism                         | Aug 2008 | Nov 2009 | PI    |
| 131) | Ironwood                | Chronic Constipation                           | Sep 2008 | May 2010 | PI    |
| 132) | Ironwood                | Chronic Constipation/IBS                       | Sep 2008 | Jun 2011 | PI    |
| 133) | Boehringer<br>Ingelheim | Atrial Fibrillation                            | Oct 2008 | Jan 2010 | PI    |
| 134) | Daiichi Sanyko          | Atrial Fibrillation                            | Jan 2009 | Nov 2010 | Sub-I |
| 135) | Ironwood                | Irritable Bowel<br>Syndrome/Constipation       | Jun 2009 | May 2010 | PI    |
| 136) | Ironwood                | Irritable Bowel<br>Syndrome/Constipation       | Jun 2009 | May 2010 | PI    |
| 137) | Ironwood                | Irritable Bowel Syndrome                       | Aug 2009 | Sep 2009 | PI    |
| 138) | Abbott                  | Chronic Kidney Disease                         | Nov 2009 | Jun 2010 | PI    |
| 139) | Novartis                | HTN/Type II Diabetes                           | Aug 2009 | Aug 2011 | Sub-I |
| 140) | Ironwood                | Chronic Constipation                           | Oct 2008 | Apr 2009 | PI    |
| 141) | Abbott                  | Dyslipidemia                                   | Jan 2010 | Aug 2010 | PI    |
| 142) | Bristol Myers Squibb    | HTN/Type II Diabetes                           | Jun 2010 | Dec 2010 | PI    |
| 143) | Bristol Myers Squibb    | HTN/Type II Diabetes                           | Oct 2010 | Dec 2010 | PI    |
| 144) | Pfizer                  | Deep Vein Thrombosis/<br>Pulmonary Embolism    | Dec 2010 | Jul 2011 | PI    |
| 145) | Novartis                | HTN/Type II Diabetes                           | Dec 2010 | Mar 2012 | Sub-I |
| 146) | Pfizer                  | Deep Vein Thrombosis/<br>Pulmonary Embolism    | Dec 2010 | Jul 2012 | PI    |
| 147) | Pozen                   | Aspirin-Associated Ulcers                      | Mar 2011 | Jun 2011 | PI    |
| 148) | Merck                   | Overactive bladder                             | May 2011 | Apr 2012 | PI    |
| 149) | Forest                  | HTN                                            | Sep 2011 | Dec 2011 | PI    |
| 150) | Boston Scientific       | Congestive Heart Failure Devise                | 2011     | 2012     | Sub-I |
| 151) | Forest                  | HTN                                            | Jan 2012 | Oct 2012 | PI    |
| 152) | Merck                   | Type II Diabetes                               | Feb 2012 | Apr 2012 | PI    |
| 153) | Forest                  | Diabetic Peripheral Neuropathic<br>Pain        | Apr 2012 | Oct 2012 | PI    |
| 154) | Sanofi                  | Hypercholesterolemia                           | Apr 2012 | Apr 2013 | PI    |

## Clinical Trial Experience: D. Eric Bolster, MD

|      |                   |                                                     |           |          |       |
|------|-------------------|-----------------------------------------------------|-----------|----------|-------|
| 155) | Furiex            | Irritable Bowel Syndrome                            | Jul 2012  | Jun 2013 | PI    |
| 156) | Pfizer            | Hypercholesterolemia                                | Sept 2012 | Nov 2012 | PI    |
| 157) | Sanofi            | Hypercholesterolemia                                | Nov 2012  | May 2012 | PI    |
| 158) | Cempra            | Pneumonia                                           | Dec 2012  | Jan 2015 | PI    |
| 159) | Repros            | Endometriosis                                       | Sep 2012  | ONGOING  | PI    |
| 160) | Synergy           | IBS with Constipation                               | Apr 2013  | May 2014 | PI    |
| 161) | Mylan             | Herpes Simplex                                      | Jun 2013  | Apr 2014 | PI    |
| 162) | Regeneron         | Hypercholesterolemia with Cardiovascular Events     | Jul 2013  | Aug 2013 | PI    |
| 163) | Regeneron         | Hypercholesterolemia with Cardiovascular Events     | Jul 2013  | Aug 2013 | PI    |
| 164) | Regeneron         | Statin Intolerant Hypercholesterolemia              | Jul 2013  | ONGOING  | PI    |
| 165) | Merck             | Metformin Intolerant Type II Diabetes Mellitus      | Jul 2013  | Jul 2014 | PI    |
| 166) | Forest            | COPD                                                | Sep 2013  | ONGOING  | Sub-I |
| 167) | Merck             | Type II Diabetes Mellitus w/ Cardiovascular Disease | Jan 2013  | ONGOING  | PI    |
| 168) | Astellas          | Overactive Bladder                                  | Jan 2014  | Feb 2016 | PI    |
| 169) | Astellas          | Overactive Bladder                                  | Jul 2014  | ONGOING  | PI    |
| 170) | Esperion          | Hypercholesterolemia/Lipidemia                      | Jul 2014  | Feb 2015 | PI    |
| 171) | Shionogi          | Opioid Induced Constipation                         | Dec 2013  | Mar 2016 | PI    |
| 172) | Pfizer            | Cholesterol                                         | Nov 2013  | ONGOING  | PI    |
| 173) | Sanofi            | Hypercholesterolemia                                | Mar 2014  | ONGOING  | PI    |
| 174) | AstraZeneca       | Asthma                                              | Jun 2014  | Jan 2016 | PI    |
| 175) | Mariner           | Deep Vein Thrombosis                                | Jun 2014  | ONGOING  | Sub-I |
| 176) | Novo Nordisk      | Diabetes Mellitus Type I                            | Jan 2014  | Aug 2015 | PI    |
| 177) | Pfizer            | Cholesterol                                         | Jun 2014  | Mar 2016 | PI    |
| 178) | Cymabay           | Gout                                                | Jun 2014  | Feb 2015 | PI    |
| 179) | AstraZeneca       | Type II Diabetes                                    | Jan 2015  | ONGOING  | Sub-I |
| 180) | Merck/Pfizer      | Type II Diabetes                                    | Jan 2015  | ONGOING  | PI    |
| 181) | Repros            | Uterine Fibroid                                     | Mar 2015  | ONGOING  | PI    |
| 182) | Daiichi Sankyo    | Fibromyalgia                                        | Mar 2015  | ONGOING  | Sub-I |
| 183) | Pfizer            | Hypercholesterolemia/Lipidemia                      | May 2015  | ONGOING  | PI    |
| 184) | Bayer Health Care | Contraception                                       | Jun 2015  | ONGOING  | Sub-I |
| 185) | Arisaph           | Cholesterol                                         | Oct 2015  | ONGOING  | PI    |
| 186) | Catabasis         | Cholesterol                                         | Oct 2015  | Jun 2016 | PI    |
| 187) | Sanofi            | DM II Toujeo                                        | Nov 2015  | ONGOING  | Sub-I |
| 188) | Elcelyx           | DM II Metformin Intolerant                          | Nov 2015  | ONGOING  | PI    |
| 189) | Egalet            | Chronic pain                                        | Jan 2016  | ONGOING  | Sub-I |
| 190) | Novo Nordisk      | DM II                                               | Feb 2016  | ONGOING  | PI    |
| 191) | Sanofi            | High Cholesterol w/ DM II                           | Mar 2016  | ONGOING  | PI    |
| 192) | Cempra            | Acute Bacterial Skin Infection                      | Jun 2016  | ONGOING  | PI    |
| 193) | Shionogi          | Vaginal Dryness                                     | Jul 2016  | ONGOING  | Sub-I |
| 194) | Braintree         | Opioid Induced Constipation                         | Jul 2016  | ONGOING  | PI    |
| 195) | Novo Nordisk      | DM II                                               | Jul 2016  | ONGOING  | PI    |



06 Jul 2016